SLC39A7 and breast carcinoma: The zinc transporter SLC39A7 (ZIP7) is activated in estrogen receptor-positive (ER+) breast cancer cells through seryl phosphorylation, which in turn stimulates pathways that are implicated in cancer progression (Taylor et al., 2012[417]; Ziliotto et al., 2018[483]).